Cspc
As of the edition of 20 October 2026, Cspc runs 61 drugs, 2 of them marketed; it is on route A at 1 target and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 8 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 41 |
| Went quiet | 4 |
| Stopped | 3 |
| Status not established | 11 |
| Total | 61 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Toripalimab | Ends 2035 (computed from the first US licence) | 2 |
| Levamlodipine | none listed | 4 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 4 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Cspc needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 36 trials led
- Nutrition and metabolism: 25 trials led
- Hormones: 20 trials led